Compare LION & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | SYRE |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2016 |
| Metric | LION | SYRE |
|---|---|---|
| Price | $8.09 | $37.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $10.06 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 2.5M | 584.9K |
| Earning Date | 02-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,954,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.38 | N/A |
| 52 Week Low | $5.55 | $10.91 |
| 52 Week High | $10.09 | $37.98 |
| Indicator | LION | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 64.27 |
| Support Level | $7.95 | $32.35 |
| Resistance Level | $9.59 | $35.58 |
| Average True Range (ATR) | 0.46 | 1.90 |
| MACD | -0.17 | 0.22 |
| Stochastic Oscillator | 7.69 | 80.88 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.